drugset / Trial / NCT05834413

Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

NCT05834413

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This project adopts a prospective, multicenter, randomized controlled clinical study to investigate the treatment of TCM in postoperative patients with driver gene negative lung cancer, according to two phases of postoperative adjuvant therapy: (i) chemotherapy phase immunotherapy phase. In this study, 367 patients (183 in the control group and 184 in the trial group) will be observed over 4 years, and the quality of life, toxic effects and safety of this therapy will be investigated. This study will provide evidence-based evidence for the establishment and optimization of a new model of postoperative staged TCM with adjuvant chemo-immunotherapy for lung cancer.

Timeline

Start
2023-05-01
Primary completion
2027-06-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject FeiPingFang Unknown Oral
Subject HeWeiYangXueFang Unknown Oral
Background Atezolizumab Monoclonal antibody
Background Camrelizumab Monoclonal antibody
Background Carboplatin Small molecule
Background Cisplatin Other / unclassified
Background Docetaxel Small molecule
Background Dupilumab Monoclonal antibody
Background Durvalumab Monoclonal antibody
Background Gemcitabine Small molecule
Background Nivolumab Monoclonal antibody
Background Paclitaxel Small molecule
Background Pembrolizumab Monoclonal antibody
Background Pemetrexed Small molecule
Background Sintilimab Monoclonal antibody
Background Tislelizumab Monoclonal antibody
Background Vincristine Small molecule

Indications